GST HG 161
Alternative Names: GST HG-161Latest Information Update: 28 Aug 2022
At a glance
- Originator Fujian Cosunter Pharmaceutical; WuXi AppTec
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer; Solid tumours
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Liver-cancer in China (PO)
- 29 May 2020 Early adverse events data from a phase I trial in Solid tumours presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)